Whitney A Spannuth
Overview
Explore the profile of Whitney A Spannuth including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
2037
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mangala L, Zuzel V, Schmandt R, Leshane E, Halder J, Armaiz-Pena G, et al.
Clin Cancer Res
. 2021 Aug;
27(15):4454.
PMID: 34341059
No abstract available.
2.
Merritt W, Kamat A, Hwang J, Bottsford-Miller J, Lu C, Lin Y, et al.
Cancer Biol Ther
. 2010 Oct;
10(12):1306-14.
PMID: 20948320
Objective: EphA2 overexpression predicts poor prognosis in endometrial cancer. To explore mechanisms for this association and assess its potential as therapeutic target, the relationship of EphA2 expression to markers of...
3.
Nick A, Schmeler K, Frumovitz M, Soliman P, Spannuth W, Burzawa J, et al.
Obstet Gynecol
. 2010 Sep;
116(4):956-961.
PMID: 20859161
Objective: To estimate the incidence of venous thromboembolism among patients undergoing gynecologic laparoscopy and characterize the risk of venous thromboembolism among patients with gynecologic malignancy. Methods: Data were collected for...
4.
Lu C, Han H, Mangala L, Ali-Fehmi R, Newton C, Ozbun L, et al.
Cancer Cell
. 2010 Aug;
18(2):185-97.
PMID: 20708159
Although VEGF-targeted therapies are showing promise, new angiogenesis targets are needed to make additional gains. Here, we show that increased Zeste homolog 2 (EZH2) expression in either tumor cells or...
5.
Spannuth W, Mangala L, Stone R, Carroll A, Nishimura M, Shahzad M, et al.
Mol Cancer Ther
. 2010 Aug;
9(8):2377-88.
PMID: 20682653
EphB4 is a transmembrane receptor tyrosine kinase that plays an important role in neural plasticity and angiogenesis. EphB4 is overexpressed in ovarian cancer and is predictive of poor clinical outcome....
6.
Sood A, Armaiz-Pena G, Halder J, Nick A, Stone R, Hu W, et al.
J Clin Invest
. 2010 Apr;
120(5):1515-23.
PMID: 20389021
Chronic stress is associated with hormonal changes that are known to affect multiple systems, including the immune and endocrine systems, but the effects of stress on cancer growth and progression...
7.
Merritt W, Nick A, Carroll A, Lu C, Matsuo K, Dumble M, et al.
Mol Cancer Ther
. 2010 Apr;
9(4):985-95.
PMID: 20371710
This study aimed to investigate the antitumor and antiangiogenic effects utilizing a novel therapy regimen of metronomic topotecan and pazopanib, a multireceptor tyrosine kinase inhibitor. In vitro (Western blot) and...
8.
Spannuth W, Sood A, Coleman R
Expert Opin Biol Ther
. 2010 Jan;
10(3):431-7.
PMID: 20092424
Importance Of The Field: Ovarian cancer is the leading cause of death from a gynecologic malignancy. Recurrence is both common and lethal, necessitating the development of novel targeted therapies. Farletuzumab...
9.
Merritt W, Danes C, Shahzad M, Lin Y, Kamat A, Han L, et al.
Cancer Biol Ther
. 2009 Sep;
8(16):1596-603.
PMID: 19738426
Purpose: Metronomic chemotherapy regimens have shown anti-tumor activity by anti-angiogenic mechanisms, however, the efficacy of metronomic topotecan in ovarian cancer is not known and the focus of the current study....
10.
Mangala L, Zuzel V, Schmandt R, Leshane E, Halder J, Armaiz-Pena G, et al.
Clin Cancer Res
. 2009 May;
15(11):3770-80.
PMID: 19470734
Purpose: Resistance to platinum chemotherapy remains a significant problem in ovarian carcinoma. Here, we examined the biological mechanisms and therapeutic potential of targeting a critical platinum resistance gene, ATP7B, using...